Rossari Biotech share price today

Rossari Biotech Ltd's share price was ₹420.40 at the close on 4 November 2026. It has been falling for 96 weeks. That is 16.1% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹398 and ₹630, and at that close it sat 10% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Rossari Biotech Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 20 weeks running.

Over the last 6.3 years the share price moved −43% while the NIFTY 500 moved +141%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 25 June 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: revenue up on a year earlier for 12 quarters in a row (every quarter we can compare), foreign funds (FIIs) cut their stake for 6 quarters in a row and indian funds and insurers (DIIs) cut their stake for 3 quarters in a row.

1. Revenue up on a year earlier for 12 quarters in a row (every quarter we can compare)

   In the September 2026 quarter revenue was ₹698 crore, +19.1% on a year earlier.

   Why: Revenue rose because all three main businesses grew, helped by selling more higher value products.

   Next results: check whether revenue grows in the mid-teens to slightly high-teens range management expects for this year.

   From the earnings call on 19 Oct 2026.

2. Foreign funds (FIIs) cut their stake for 6 quarters in a row

   From 4% to 1.8% of the company by the September 2026 quarter.

3. Indian funds and insurers (DIIs) cut their stake for 3 quarters in a row

   From 18.3% to 14.2% of the company by the September 2026 quarter.

For July to September 2026 (the quarter ended 30 September 2026), Rossari Biotech reported revenue of ₹698 crore, up 19.1% from ₹586 crore a year earlier, and a profit of ₹39.0 crore, up 5.4% from ₹37.0 crore.

Rossari Biotech results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Rossari Biotech's management discussed these results on a call held on 19 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Rossari Biotech closed at ₹420.40 on 4 November 2026, down 33.0% from ₹627.60 a year earlier (7 November 2025) and down 69.2% over five years. Its highest weekly close since July 2020 was ₹1,527.45 on 14 October 2021.

Rossari Biotech share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

335 weekly closes from 24 July 2020 to 4 November 2026.

4 Nov 2026: Rossari Biotech closed at ₹420.40, up 5.3% on the week and down 1.7% on the month. 19 Oct 2026: Rossari Biotech held its results call for July to September 2026. Management guided: FY27 full-year consolidated operating margin around 12% plus or minus.

Earlier

• Results for July to September 2026: Revenue up 19.1% and profit up 5.4% on a year earlier.
• 10 Jul 2026: ex-date for a dividend of ₹0.50 a share.

Rossari Biotech paid ₹0.50 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.12% at the ₹420.40 close on 4 November 2026. The last was a dividend of ₹0.50 a share, ex-date 10 July 2026.

Rossari Biotech dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Yes. Rossari Biotech Ltd paid out 2% of its profit as dividends in FY26, and it paid a dividend in 7 of its last 8 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for July to September 2026, held on 19 October 2026, Rossari Biotech's management guided: FY27 full-year consolidated operating margin around 12% plus or minus.

“We expect the Reliance expansion to come into operation in the first quarter of the next financial year, and we should receive a higher amount of EO allocation from that quarter.”Management, on the call for July to September 2026

What management guided

• FY27 revenue growth in mid-teens to slightly high-teens versus 12-14% start-year view.
• Exports at least 30% of revenue by end of this year.
• New ethoxylation to peak by end-FY28 at 3x capital spending peak sales; Reliance Q1 next FY to lift allocation for healthy use by Q2-Q3 next year.
• Institutional H2 operating profit-positive to secure full-year breakeven after Q1 loss.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 19 October 2026.

When Rossari Biotech reports October to December 2026, these are the check that show whether the story is still on course. First: Institutional business H2 operating profit positivity to secure full-year breakeven after flagged early-year loss on mix and costs.

Rossari Biotech is not on any of our India lists this week.

Rossari Biotech Ltd earned ₹39.0 Cr of net profit in the Sep 2026 quarter, +5.4% on the same quarter a year earlier. That is the 5th quarter in a row of profit growth. Full-year FY26 profit was ₹149 Cr. Over 7 years profit has grown 18.3% a year on average. That is 5.6% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹37.0 Cr.

For the full year, FY26 profit was ₹149 Cr (+9.6% on the year before).

Why profit moved: revenue changed +19.1% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +11.7% and revenue +19.7%. Profit is growing slower than sales: rising costs are taking part of the growth.

Rossari Biotech Ltd reported ₹698 Cr of revenue in the Sep 2026 quarter, +19.1% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 7 years it has grown 24.5% a year on average. The last full year, FY26, came in at ₹2,396 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹2,662 Cr.

FY26 revenue was ₹2,396 Cr, +15.2% on the year before.

Recent pace: the last four quarters grew +19.7% on average, against 24.5% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +19.7%, against +17.6% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +11.7%, against +5.3% a year (accelerating).

Rossari Biotech Ltd's operating margin was 12.0% in the Sep 2026 quarter, about the same as the same quarter a year ago. Across 8 years it has been between 12.0% and 17.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

In the latest quarter it moved +0.0 percentage points on the same quarter a year ago.

Why the margin moved: operating margin changed +0.2 percentage points on the year while gross margin changed +0.0 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 59% of Rossari Biotech Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹65.0 Cr of operating cash against ₹149 Cr of profit. After ₹298 Cr of spending on assets, free cash was −₹233 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 59% of profit came in as cash: the cash cycle got 57 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 57 days longer. The next section looks at where the cash is stuck.

Rossari Biotech Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 103 days in FY26, up from 46 days in FY21. It spent ₹562 Cr on assets over the last 3 years. Customers take 85 days to pay, and stock sits for 88 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹2,396 Cr, each day of that cycle ties up about ₹6.6 Cr, so roughly ₹676 Cr is tied up in the business at any time.

FY26: customers took 85 days to pay and stock sat for 88 days, about 2.9 months of sales sitting as stock, for a full cycle of 103 days, longer than FY21's 46.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 88 days. Customers pay about 85 days after that. Suppliers are paid at 71 days. Together that makes the 103-day cycle.

Spending on assets: ₹562 Cr over the last 3 years, against ₹206 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹173 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

Rossari Biotech Ltd's P/E is 15.3×, about the lowest it has ever been. Its usual P/E (the middle reading) is 37.0×, over 6.3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Why the multiple is where it is: over the past year earnings per share moved +9.4% while the price moved −33.0%. Earnings did better than the price, which pulled the multiple down within its own range.

Where the price move came from: over 5 years the price moved −21.0% a year; about +11.2% a year came from earnings growth and about −32.2 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.

Rossari Biotech Ltd's business is growing steadily. Revenue, profit and EPS growth have stayed positive throughout, and ROCE is steady at 16.1%. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: steady growth with healthy returns is how a business compounds over time.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Rossari Biotech Ltd earned a ROCE of 13% in FY26. Its return on capital used (ROIC) is 3.0 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 6.2% net margin and 1.05× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 6.2% net margin × 1.05× asset turnover × 1.71× leverage (assets divided by equity) ≈ 11.1% on equity. The margin does its share; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 9.0% − 12.0% = −3.0 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

Rossari Biotech Ltd has total debt of ₹388 Cr against shareholder equity of ₹1,408 Cr as of Sep 2026, so its debt is 0.28× its equity, which is very little. Year by year, that ratio went from 0.01 in FY22 to 0.33 in FY26. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

Domestic institutions cut their stake in Rossari Biotech Ltd by 3.2 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 14.2% of the company. Foreign institutions moved −1.9 points over the same period, to 1.8%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Domestic institutions: −3.2 points over 8 quarters, to 14.2%; Foreign institutions: −1.9 points over 8 quarters, to 1.8%; Promoters: −0.1 points over 8 quarters, to 68.1%.

Why the owners changed: domestic institutions drove it (−3.2 points), together with foreign institutions (−1.9 points). They reduced their stake.

For Rossari Biotech Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

47.7 out of 100, rank 3 of 3 in Seeds/Tissue Culture/Bio Technology, with 97% of the evidence available.

Rossari Biotech Ltd scores 47.7 out of 100 against the 3 companies it is compared with in Seeds/Tissue Culture/Bio Technology, ranking 3. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.

The four parts add up to the total exactly: 19.4 + 13.4 + 14.9 + 0 = 47.7. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Rossari Biotech ranks 3 of 3 Seeds/Tissue Culture/Bio Technology companies on the 4-Factor Sector Score, with 47.7 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Seeds/Tissue Culture/Bio Technology, all 3 compared on one page.

Rossari Biotech is the 2nd largest of 3 Seeds/Tissue Culture/Bio Technology companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Advanced Enzyme Technologies. Just below it: Bombay Super Hybrid Seeds.

Seeds/Tissue Culture/Bio Technology companies close in size

1. Advanced Enzyme Technologies Ltd ₹2,951 crore
2. Rossari Biotech Ltd ₹2,212 crore
3. Bombay Super Hybrid Seeds Ltd ₹873 crore

All 3 Seeds/Tissue Culture/Bio Technology companies, largest first

Companies close in size in other industries

1195. Pix Transmission Ltd ₹2,229 crore · Rubber Processing/Rubber Products
1196. Dhenu Buildcon Infra Ltd ₹2,213 crore · NBFC - Others
1197. Rossari Biotech Ltd ₹2,212 crore
1198. Somany Ceramics Ltd ₹2,211 crore · Ceramics/Tiles/Sanitaryware
1199. Anantam Highways Trust ₹2,209 crore · Infra/Real Estate Investment Trust

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.